Myriad Genetics Affirms FY2026 Sales Guidance of $860.000M-$880.000M vs $864.099M Est

Benzinga Newsdesk www.benzinga.com Negative 81.9%

Neg 81.9% Neu 0% Pos 0%

Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $860.000 million-$880.000 million to $860.000 million-$880.000 million vs $864.099 million estimate.